Molecular Subtypes and Personalized Therapy in Metastatic Colorectal Cancer.

ABSTRACT: Development of colorectal cancer occurs via a number of key pathways, with the clinicopathological features of specific subgroups being driven by underlying molecular changes. Mutations in key genes within the network of signalling pathways have been identified; however, therapeutic strategies to target these aberrations remain limited. As understanding of the biology of colorectal cancer has improved, this has led to a move toward broader genomic testing, collaborative research and innovative, adaptive clinical trial design. Recent developments in therapy include the routine adoption of wider mutational spectrum testing prior to use of targeted therapies and the first promise of effective immunotherapy for colorectal cancer patients. This review details current biomarkers in colorectal ca

SUBMITTER: Graham DM 

PROVIDER: S-EPMC4879165 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature